INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation
NASDAQ:INDV • US45579U1097
Current stock price
31.945 USD
+0.98 (+3.15%)
Last:
This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. INDV Profitability Analysis
1.1 Basic Checks
- In the past year INDV was profitable.
- In the past year INDV had a positive cash flow from operations.
- In multiple years INDV reported negative net income over the last 5 years.
- In multiple years INDV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 8.62%, INDV belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
- INDV has a better Return On Invested Capital (50.62%) than 100.00% of its industry peers.
- INDV had an Average Return On Invested Capital over the past 3 years of 43.06%. This is significantly above the industry average of 12.98%.
- The last Return On Invested Capital (50.62%) for INDV is above the 3 year average (43.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROIC | 50.62% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
1.3 Margins
- The Profit Margin of INDV (10.34%) is better than 84.90% of its industry peers.
- INDV's Profit Margin has declined in the last couple of years.
- INDV has a better Operating Margin (24.49%) than 92.19% of its industry peers.
- INDV's Operating Margin has been stable in the last couple of years.
- With an excellent Gross Margin value of 85.51%, INDV belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
- INDV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% |
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
2. INDV Health Analysis
2.1 Basic Checks
- INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- INDV has an Altman-Z score of 2.56. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
- INDV has a better Altman-Z score (2.56) than 67.19% of its industry peers.
- INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
- INDV's Debt to FCF ratio of 2.68 is amongst the best of the industry. INDV outperforms 92.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 2.56 |
ROIC/WACC5.24
WACC9.67%
2.3 Liquidity
- INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
- INDV has a Current ratio of 0.96. This is amonst the worse of the industry: INDV underperforms 84.38% of its industry peers.
- A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
- With a Quick ratio value of 0.79, INDV is not doing good in the industry: 81.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 |
3. INDV Growth Analysis
3.1 Past
- INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
3.2 Future
- Based on estimates for the next years, INDV will show a decrease in Earnings Per Share. The EPS will decrease by -3.07% on average per year.
- INDV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.79% yearly.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%
3.3 Evolution
4. INDV Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 12.99, which indicates a correct valuation of INDV.
- Based on the Price/Earnings ratio, INDV is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of INDV to the average of the S&P500 Index (25.96), we can say INDV is valued slightly cheaper.
- The Price/Forward Earnings ratio is 10.37, which indicates a very decent valuation of INDV.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.54% of the companies listed in the same industry.
- INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.99 | ||
| Fwd PE | 10.37 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 84.90% of the companies are valued more expensively.
- INDV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INDV is cheaper than 80.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.29 | ||
| EV/EBITDA | 11.91 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of INDV may justify a higher PE ratio.
- INDV's earnings are expected to grow with 13.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%
5. INDV Dividend Analysis
5.1 Amount
- INDV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INDV Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:INDV (3/17/2026, 10:11:08 AM)
31.945
+0.98 (+3.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)04-22 2026-04-22
Inst Owners86.43%
Inst Owner Change-70.46%
Ins Owners3.62%
Ins Owner Change39.53%
Market Cap4.00B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (45.5%)
Short Float %8.33%
Short Ratio4.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.86%
EPS NY rev (3m)3.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.99 | ||
| Fwd PE | 10.37 | ||
| P/S | 3.39 | ||
| P/FCF | 33.29 | ||
| P/OCF | 22.2 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.91 |
EPS(TTM)2.46
EY7.7%
EPS(NY)3.08
Fwd EY9.65%
FCF(TTM)0.96
FCFY3%
OCF(TTM)1.44
OCFY4.51%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.51
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROCE | 64.08% | ||
| ROIC | 50.62% | ||
| ROICexc | 3805.17% | ||
| ROICexgc | 5707.75% | ||
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% | ||
| FCFM | 10.17% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 0.97 | ||
| Cap/Depr | 230.77% | ||
| Cap/Sales | 5.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 57.14% | ||
| Profit Quality | 98.36% | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 2.56 |
F-Score8
WACC9.67%
ROIC/WACC5.24
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1051.87%
EBIT Next 3Y148.64%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%
INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ
What is the fundamental rating for INDV stock?
ChartMill assigns a fundamental rating of 5 / 10 to INDV.
What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?
ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.
What is the profitability of INDV stock?
INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.
How financially healthy is INDIVIOR PHARMACEUTICALS INC?
The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.
Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?
The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.